Business Context and Reporting Period
This Form 8-K Current Report was filed by Halozyme Therapeutics, Inc. on December 13, 2005. The filing discloses the entry into a material definitive agreement regarding a registered direct offering of common stock.
Key Financial Metrics
The filing details a specific capital raise transaction rather than periodic financial performance metrics such as revenue or operating profit.
- Offering Size: 828,571 shares of common stock.
- Price Per Share: $1.75.
- Gross Proceeds: Approximately $1.45 million.
- Expected Closing Date: December 16, 2005.
- Placement Agents: SG Cowen & Co., LLC, Rodman & Renshaw, LLC, and Roth Capital Partners, LLC.
Material Changes and Context
This transaction is an additional offering to a larger registered direct offering announced on December 12, 2005. The prior offering involved commitments to purchase 9,171,429 shares for gross proceeds of approximately $16.1 million. The shares in this filing are being issued pursuant to a shelf registration statement (Form S-3) effective June 17, 2005.
Use of Proceeds and Management Commentary
Management indicated that the net proceeds from this offering will be utilized for:
- Research and development activities.
- Clinical trials.
- Other working capital and general corporate purposes.
The filing does not provide specific guidance on future revenue, profit margins, or liquidity ratios beyond the immediate cash infusion from this transaction.
Investor Verification Checklist
- Verify the closing of the offering on or about December 16, 2005.
- Confirm the total dilution impact by combining this offering (828,571 shares) with the prior December 12 offering (9,171,429 shares).
- Review the Placement Agent Agreement (Exhibit 10.1) for specific fees and commissions deducted from the gross proceeds.
- Monitor subsequent filings for updates on the utilization of funds for clinical trials and R&D.